Scientific paper - Review paper
Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE
European Archives of Oto-Rhino-Laryngology, 276 (2019), 5; 1275-1281. https://doi.org/10.1007/s00405-019-05387-8


Cite this document

Suton, P., Skelin, M., Rakušić, Z., Dokuzović, S. & Lukšić, I. (2019). Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. European Archives of Oto-Rhino-Laryngology, 276. (5), 1275-1281. doi: 10.1007/s00405-019-05387-8

Suton, Petar, et al. "Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE." European Archives of Oto-Rhino-Laryngology, vol. 276, no. 5, 2019, pp. 1275-1281. https://doi.org/10.1007/s00405-019-05387-8

Suton, Petar, Marko Skelin, Zoran Rakušić, Stjepan Dokuzović and Ivica Lukšić. "Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE." European Archives of Oto-Rhino-Laryngology 276, no. 5 (2019): 1275-1281. https://doi.org/10.1007/s00405-019-05387-8

Suton, P., et al. (2019) 'Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE', European Archives of Oto-Rhino-Laryngology, 276(5), pp. 1275-1281. doi: 10.1007/s00405-019-05387-8

Suton P, Skelin M, Rakušić Z, Dokuzović S, Lukšić I. Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE. European Archives of Oto-Rhino-Laryngology [Internet]. 2019 May [cited 2024 June 23];276(5):1275-1281. doi: 10.1007/s00405-019-05387-8

P. Suton, M. Skelin, Z. Rakušić, S. Dokuzović and I. Lukšić, "Cisplatin-based chemoradiotherapy vs. cetuximab-based bioradiotherapy for p16-positive oropharyngeal cancer: an updated meta-analysis including trials RTOG 1016 and De-ESCALaTE", European Archives of Oto-Rhino-Laryngology, vol. 276, no. 5, pp. 1275-1281, May 2019. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:503286. [Accessed: 23 June 2024]